Chemed Corporation Surges 12% on Earnings Beat and Raised Guidance
NEW YORK, April 25 —
Chemed Corporation (CHE) jumped roughly 12% after beating Q1 estimates, raising full-year guidance, and buying two Roto-Rooter franchises.
- Q1 EPS and revenue both topped consensus, prompting a full-year 2026 guidance raise
- At $421.11 and 15.8x forward P/E, Chemed trades at a premium for what is partly a plumbing company
- Next test: VITAS admissions growth and Roto-Rooter marketing costs in Q2
What Actually Happened
Chemed is two businesses bolted together: VITAS, one of the largest hospice providers in the U.S., and Roto-Rooter, the plumbing and drain cleaning franchise. VITAS carried the load this quarter. Hospice admissions growth drove the revenue beat. Roto-Rooter held steady, though rising marketing costs ate into margins.
The franchise acquisitions matter for what they signal. Chemed bought two Roto-Rooter franchises serving 3.3 million people, folding independent operators back into the corporate system. The playbook: buy back franchises, capture the full margin instead of collecting royalties. It's slow, quiet consolidation that doesn't make headlines but compounds over years.
Management raised full-year guidance — that's the real reason the stock popped 12%. A Q1 beat alone wouldn't do it. The guidance raise says they expect the hospice strength to hold through the year.
The Catch
Roto-Rooter's marketing cost pressure deserves scrutiny. The plumbing business competes for local search clicks against every independent operator with a Google Ads budget. Customer acquisition costs in home services have been climbing industry-wide. Roto-Rooter isn't immune. If VITAS ever posts a soft quarter, that margin squeeze on the plumbing side becomes the whole story.
Then there's valuation. At 15.8x forward earnings and $2.5bn in TTM revenue, Chemed isn't cheap for a company where half the business sends trucks to unclog drains. Investors are paying a hospice multiple for the whole entity. That works when VITAS is accelerating. It stops working if admissions growth slows.
Bottom Line
This is a clean quarter from a well-run, boring company. An earnings beat, raised guidance, and accretive acquisitions — that's exactly what long-term holders want. Chemed won't double in a year. It grinds higher when both segments perform. The stock looks more interesting after this print, especially for investors who want healthcare exposure without biotech risk.
The number to track next quarter: VITAS admissions growth rate. That's the engine. Everything else is plumbing.
There's no existing deep-dive report for Chemed. Generate a full Chemed (CHE) report here to see the complete financial picture.
Basis Report does not hold positions in securities discussed. This is not investment advice.